141 related articles for article (PubMed ID: 8773615)
1. Deprenyl's neuroprotective action remains unresolved.
van Hilten JJ; Bloem BR; Klaassen AA
Ann Neurol; 1996 Aug; 40(2):266-7. PubMed ID: 8773615
[No Abstract] [Full Text] [Related]
2. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois B; Montastruc JL
Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
[No Abstract] [Full Text] [Related]
3. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
4. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
5. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Olanow CW; Mytilineou C; Tatton W
Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
[No Abstract] [Full Text] [Related]
6. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
7. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
Ben-Shlomo Y; Lees A;
Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
[No Abstract] [Full Text] [Related]
8. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
9. Selegiline and excess mortality.
Oakes D
Clin Neuropharmacol; 1997 Dec; 20(6):542. PubMed ID: 9403228
[No Abstract] [Full Text] [Related]
10. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
11. Current and future approaches to therapy.
Birkmayer W; Birkmayer JD
Adv Neurol; 1987; 45():511-2. PubMed ID: 3103393
[No Abstract] [Full Text] [Related]
12. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
Breteler MM
BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
[No Abstract] [Full Text] [Related]
13. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
14. Placebo response in Parkinson trials using patient diaries: sites do matter.
Ondo WG
Clin Neuropharmacol; 2007; 30(5):301-4. PubMed ID: 17909309
[No Abstract] [Full Text] [Related]
15. Unexpected findings of study of selegiline have not been treated with caution its authors advised.
Silva MT; Schapira AH; Jenner P
BMJ; 1997 Aug; 315(7104):370. PubMed ID: 9270472
[No Abstract] [Full Text] [Related]
16. [If I were to wake-up clumsy and trembling...(or how to begin treatment of Parkinson disease].
Linazasoro G
Neurologia; 1998; 13(6):265-70. PubMed ID: 9734197
[No Abstract] [Full Text] [Related]
17. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Heinonen E; Myllylä V
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
[No Abstract] [Full Text] [Related]
18. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Coyle J; Hobson P; Meara J
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
[No Abstract] [Full Text] [Related]
19. Selegiline slows the progression of the symptoms of Parkinson disease.
Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
[TBL] [Abstract][Full Text] [Related]
20. Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects.
Prescrire Int; 2003 Oct; 12(67):179. PubMed ID: 14619897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
